CORPUS CHRISTI, TX (May 17, 2013) –Thomas J. Henry is investigating cases of renal failure, some resulting in the need for dialysis, in patients enrolled in the Bristol Myers Squibb BMS-986094 clinical trials for Hepatitis C.

Thomas J. Henry is representing victims across the United States who were injured in the BMS-986094 clinical trials. The firm continues to investigate the drug’s rocky journey toward FDA approval, which began with Inhibitex purchasing the development rights from Cardiff University in 2007 (Inhibitex was subsequently bought out by Bristol Myers Squibb in 2012) and ended abruptly in September 2012 when a patient died of heart failure during a BMS Phase II clinical trial for the drug.

BMS-986094 (formerly known as INX-08189) was being tested on humans in Phase II of a clinical trial when the study was suspended early amid reports of one death and eight other patient hospitalizations, some for heart and kidney toxicity.

INJURIES REPORTED IN BMS-986094 TRIALS

• Fatigue
• Nausea/vomiting
• Shortness of breath
• Decreased urine production
• Kidney damage
• Renal Failure
• Swelling of the legs
• Feelings of anxiety
• Heart palpitations
• Chest pain
• Abnormal heart rhythm
• Valve inflammation
• Cardiomyopathy
• Heart damage
• Heart attack
• Heart failure
• Death

BMS-986094 TRIALS WERE HELD THROUGHOUT THE UNITED STATES

Locations of the BMS-986094 trials include:

• Montgomery, AL
• Augusta, GA
• Asheville, NC
• Tulsa, OK
• Arlington, TX
• Hoover, AL
• Anaheim, CA
• La Jolla, CA
• San Diego, CA
• San Francisco, CA
• Orlando, FL
• Atlanta, GA
• New York, NY
• Portland, OR
• Austin, TX
• San Antonio, TX
• Fairfax, VA
• Newport News, VA
• Seattle, WA